ADARX Pharmaceuticals: 52‑Week Low, Negative P/E, and Investor Scrutiny in 2026
ADARX Pharmaceuticals’ stock hits a 52‑week low at $13.23 amid negative P/E, raising investor concerns but hinting at future growth opportunities.
2 minutes to read
ADARX PHARMACEUTICALS INC